Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Orphan Medicine Mogamulizumab

It is indicated for the treatment of patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy
28 Sep 2018
Haematologic malignancies;  Cancer Immunology and Immunotherapy

On 20 September 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product mogamulizumab (Poteligeo), intended for the treatment of mycosis fungoides (MF) or Sézary syndrome (SS), the most common subsets of cutaneous T-cell lymphoma, a rare form of non-Hodgkin’s lymphoma.

Poteligeo was designated as an orphan medicinal product on 14 October 2016.

The applicant for this medicinal product is Kyowa Kirin Limited.

Poteligeo will be available as a 4-mg/ml concentrate for solution for infusion. The active substance of Poteligeo is mogamulizumab, a monoclonal antibody (ATC code: L01XC25)

that selectively binds to CC chemokine receptor-4 (CCR4) expressed on the surface of some cancer cells including T-cells of T-cell malignancies, such as MF and SS, resulting in depletion of the target cells.

The benefits with Poteligeo are its ability to improve progression-free survival in patients.

The most common side effects are drug eruption (including skin rash), infections (including upper respiratory tract infection and skin infections), infusion related reaction, headache, fatigue, peripheral oedema, pyrexia and gastrointestinal disorders (such as constipation, diarrhoea, nausea, stomatitis).

The full indication is:

Poteligeo is indicated for the treatment of adult patients with MF or SS who have received at least one prior systemic therapy.

It is proposed that Poteligeo be prescribed by physicians experienced in the treatment of cancer.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Last update: 28 Sep 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.